Jazz Pharma Q2 2026: record revenue $1.2B (+16% YoY); raises FY2026 guidance to $4.60-$4.75B

Jazz Pharmaceuticals plc

Total revenues of $1.2B, a record, up 16% YoY; GAAP EPS $2.78, non-GAAP adjusted EPS $5.71.
Xywav revenues +13% YoY with 525 net patient adds in Q2; Epidiolex revenues +16% YoY.
Company raises 2026 revenue guidance to $4.60-$4.75B, reflecting double-digit growth from Xywav and epilepsy/oncology.
FDA set PDUFA date of Aug 25, 2026 for zanidatamab sBLA in 1L GEA; BTD granted for HER2+ CRC.
Cash from operations $824M in first half 2026; strong balance sheet supports pipeline and launches.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.